CEO Today Healthcare Awards

www.ceotodaymagazine.com 60 CEO Today Healthcare Awards 2018 USA FIRM PROFILE At Horizon Pharma, we define our success by a different set of numbers: the number of lives touched, the number of lives changed, the number of lives saved. As we build a growing pipeline and explore all potential uses for our rare disease, rheumatology and primary care medicines, we strive to make a powerful difference for our patients, their caregivers and physicians every day. Our drive to deliver breakthrough medicines comes from our deep understanding of the patient journey. At Horizon, many of us know a patient, are a patient or have been impacted by a patient story. That’s why for us, it’s personal. Our History Founded in 2008 as a startup with only a handful of employees and no office space, Horizon now has over 1,000 employees and 11 medicines that treat rare and rheumatic conditions. Though we’ve grown, our culture is no different today than it was when we started. We remain personally invested in the lives of people our medicines help wherever they are in their journey, from diagnosis through ongoing care. For the full story of our founding, join CEO Tim Walbert and members of the original Horizon team as they take us back to where it all began. Putting the Patient First For Horizon, true impact is about the culture we’ve created that always puts patients at the center. The outcomes we achieve – and the lengths we go to get there – reflect our fierce determination to make a difference for the patients and communities we serve. We create meaningful change by bringing patients into the fold, knowing they’ll always have insights we won’t have. By making the patient experience a critical part of everything we do, we’re living up to our greatest potential and helping others live up to theirs. TIMOTHY WALBERT CEO of Horizon Pharma ABOUT TIMOTHY WALBERT Tim joined Horizon Pharma in June 2008 as president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma plc, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Tim served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi- indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Tim served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, Pa. He serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and serves on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is also a member of the Illinois Innovation Council. “Founded in 2008 as a startup with only a handful of employees and no office space, Horizon now has over 1,000 employees and 11 medicines that treat rare and rheumatic conditions. “ www.horizonpharma.com